Did You Lose Money Investing in Chemours (CC)?
A securities class action has been filed on behalf of all persons who purchased or otherwise acquired securities of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”).
The action, Darcy v. The Chemours Company, et al., Case No. 1:26-cv-01299, was filed on October 8, 2026 in the U.S. District Court for the District of Delaware, and asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder.
What Does the Chemours Securities Class Action Allege?
According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: 1) Defendants had materially overstated aftermarket demand for their Opteon products; 2) demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year; 3) as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and 4) consequently, Defendants’ public statements were materially false and misleading at all relevant times.
The complaint further alleges that the truth concerning demand for Chemours’s Opteon products and the Company’s financial outlook began to emerge in August 2026.
On August 4, 2026, after market hours, Chemours, according to the complaint, announced second quarter 2026 financial results. Among other things, the Company reduced its adjusted EBITDA full-year guidance to $775 million to $825 million (from $800 million to $900 million previously). Further, in the accompanying earnings call, management admitted that “[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026.” Management further disclosed “from the Q2 and Q3 perspective, there’s probably about $65 million of aftermarket sales that realistically, you think about like-for-like probably should have been allocated to more of this year.”
On this news, Chemours’s stock price fell $3.34 per share, or 18.63%, to close at $14.59 per share on August 5, 2026.
December 7, 2026 Lead Plaintiff Deadline
Chemours investors have until December 7, 2026 to move the Court to seek appointment as lead plaintiff. Investors do not need to seek appointment as lead plaintiff to remain a member of the proposed class.
Chemours Investors: Contact Kehoe Law Firm
If you purchased Chemours securities during the Class Period and suffered financial losses, you are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to learn more about the class action and your legal rights.
For a free, no-obligation legal evaluation, contact:
Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and ERISA and retirement-plan litigation. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.
Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.
SEND US A MESSAGE
Contact Us
ADDRESS
Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103